294
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Systematic development of pH-independent controlled release tablets of carvedilol using central composite design and artificial neural networks

, , &
Pages 1207-1216 | Received 01 Jan 2012, Accepted 18 Jun 2012, Published online: 18 Jul 2012

References

  • Baek IH, Yun MH, Yun HY, Kwon KI. (2008). Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of β blockers in humans. Arch Pharm Res, 31:814–821.
  • White R, Bradnam V. Handbook of drug administration via enteral feeding tubes. London: Pharmaceutical Press, 2007: 136–137.
  • Shewale BD, Sapkal NP, Raut NA, Gaikwad NJ, Fursule RA. (2008). Effect of hydroxylpropyl-β-cyclodextrin on Solubility of Carvedilol. Indian J Pharm Sci, 70:255–257.
  • Gutsche S, Krause M, Kranz H. (2008). Strategies to overcome pH-dependent solubility of weakly basic drugs by using different types of alginates. Drug Dev Ind Pharm, 34:1277–1284.
  • Kranz H, Guthmann C, Wagner T, Lipp R, Reinhard J. (2005). Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug. Eur J Pharm Sci, 26:47–53.
  • Varma MV, Kaushal AM, Garg S. (2005). Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices. J Control Release, 103:499–510.
  • Takka S, Rajbhandari S, Sakr A. (2001). Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eur J Pharm Biopharm, 52:75–82.
  • Jagdale SC, Agavekar AJ, Pandya SV, Kuchekar BS, Chabukswar AR. (2009). Formulation and evaluation of gastroretentive drug delivery system of propranolol hydrochloride. AAPS PharmSciTech, 10:1071–1079.
  • Huang YB, Tsai YH, Lee SH, Chang JS, Wu PC. (2005). Optimization of pH-independent release of nicardipine hydrochloride extended-release matrix tablets using response surface methodology. Int J Pharm, 289:87–95.
  • Streubel A, Siepmann J, Dashevsky A, Bodmeier R. (2000). pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets. J Control Release, 67:101–110.
  • Singh B, Kapil R, Nandi M, Ahuja N. (2011). Developing oral drug delivery systems using formulation by design: Vital precepts, retrospect and prospects. Expert Opin Drug Deliv, 8:1341–1360.
  • Singh B, Rani A, Babita, Ahuja N, Kapil R. (2010). Formulation optimization of hydrodynamically balanced oral controlled release bioadhesive tablets of tramadol hydrochloride. Sci Pharm, 78:303–323.
  • Singh B, Ahuja N. (2002). Development of controlled-release buccoadhesive hydrophilic matrices of diltiazem hydrochloride: Optimization of bioadhesion, dissolution, and diffusion parameters. Drug Dev Ind Pharm, 28:431–442.
  • Sun Y, Peng Y, Chen Y, Shukla AJ. (2003). Application of artificial neural networks in the design of controlled release drug delivery systems. Adv Drug Deliv Rev, 55:1201–1215.
  • Rowe RC, Roberts RJ. (1998). Artificial intelligence in pharmaceutical product formulation: Neural computing and emerging technologies. Pharm Sci Tech Tod 1:200–205.
  • Ibric S, Jovanovic M, Djuric Z, Parojcic J, Petrovic SD, Solomun L et al. (2003). Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance. AAPS PharmSciTech, 4:E9.
  • Mandal U, Gowda V, Ghosh A, Bose A, Bhaumik U, Chatterjee B et al. (2008). Optimization of metformin HCl 500 mg sustained release matrix tablets using Artificial Neural Network (ANN) based on Multilayer Perceptrons (MLP) model. Chem Pharm Bull, 56:150–155.
  • Kachrimanis K, Karamyan V, Malamataris S. (2003). Artificial neural networks (ANNs) and modeling of powder flow. Int J Pharm, 250:13–23.
  • United States Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. (1996). ICH Q2B International Conference on Harmonization Validation of Analytical Procedures: Methodology.
  • Gölcü A. (2008). New, simple and validated UV-Spectrophotometric method for estimation of some β blockers in bulk and formulations. J Analyt Chem, 63:538–543.
  • Causon R. (1997). Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J Chromatogr B Biomed Sci Appl, 689:175–180.
  • Ahuja N, Katare OP, Singh B. (2007). Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur J Pharm Biopharm, 65:26–38.
  • Shoaib MH, Tazeen J, Merchant HA, Yousuf RI. (2006). Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC. Pak J Pharm Sci, 19:119–124.
  • Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. (1983). Mechanisms of solute release from porous hydrophili cpolymers. Int J Pharmaceut, 15:25–35.
  • United States Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. (1997). Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms.
  • Kuchekar BS, Boldhane SP. (2009). Preformulation and formulation studies of novel pH-independent controlled release drug delivery system of quetiapine fumarate. J Phar Res, 2:110–119.
  • Siepe S, Lueckel B, Kramer A, Ries A, Gurny R. (2008). Assessment of tailor-made HPMC-based matrix minitablets comprising a weakly basic drug compound. Drug Dev Ind Pharm, 34:46–52.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.